Studies show the ExSpiron’s quantitative measurements of respiration demonstrate value in a number of clinical settings
Company receives additional FDA Clearance
Waltham, Mass. – July 9, 2013 – Data supporting the accuracy and utility of the new ExSpiron 1Xi monitoring system continues to mount with presentations at major medical conferences. At the International Anesthesia Research Society Meeting held May 4-7 in San Diego, CA, four separate presentations demonstrated the ExSpiron system’s utility in a variety of intra-operative and post-operative settings. Respiratory Motion conducted studies with physicians from Massachusetts General Hospital and Tufts Medical Center in Boston, MA, and Vidant Medical Center in Greenville, NC. Clinicians presented data that showed the ExSpiron is able to report decreases in respiration following narcotic administration in both cardiac and orthopedic surgery patients.